BIOCOM Announces New Board Members
04 Avril 2007 - 3:00PM
PR Newswire (US)
SAN DIEGO, April 4 /PRNewswire/ -- BIOCOM, the association for the
Southern California life science community, is pleased to announce
eight new members of its 2007-2008 Board of Directors, representing
the leadership of the life science industry. The chairman of
BIOCOM's board for 2007-2008 is Greg Lucier, president and CEO of
Carlsbad-based Invitrogen (NASDAQ:IVGN). "I am excited to continue
to work with the strongest and most accomplished board of directors
in the industry," said Joe Panetta, president and CEO of BIOCOM.
"Their guidance and oversight will continue to build on our
association's growth throughout the region as San Diego prepares to
host BIO 2008." BIOCOM's board officers and board of directors
consist of more than 50 leaders in the Southern California life
science community. Life Director: William Rastetter, Ph.D. Venture
Partner Venrock Associates Bill Rastetter joined Venrock in 2006 as
a Venture Partner. Rastetter comes to Venrock from Biogen Idec,
where he was most recently executive chairman. Rastetter joined
Idec Pharmaceuticals at its founding and grew it to a
multi-billion-dollar market valuation company, while serving as
president and CEO. Rastetter, a former chairman of BIOCOM's board,
is currently chairman of the board of Illumina, Inc, a
Venrock-invested company. He holds an S.B. in Chemistry from
M.I.T., Phi Beta Kappa, Phi Lambda Upsilon, and a M.A. and Ph.D. in
chemistry from Harvard University. Industry Directors: David Broad,
Ph.D. Vice President, General Manager Oceanside Product Operations
Genentech Inc. David Broad serves as vice president and general
manager for Genentech's Oceanside Product Operations facility. He
joined Genentech (NYSE:DNA) with the acquisition of the Oceanside
manufacturing facility from Biogen Idec and had been vice president
and general manager of Biogen Idec's West Coast Manufacturing
Operations since 2000. He holds a bachelor of science and a
Doctorate in Microbiology from the University of London, where he
was also a postdoctoral fellow. Les Cross CEO and President DJ
Orthopedics Leslie H. Cross, has been the chief executive officer,
president and a director of DJ Orthopedics (NYSE:DJO), since August
2001. He served as the chief executive officer of DonJoy, L.L.C.,
the predecessor of the company, from June 1999 until November 2001,
and has served as president of DJ Orthopedics, LLC, the company's
wholly-owned operating subsidiary. Cross earned a diploma in
Medical Technology from Sydney Technical College in Sydney,
Australia and studied Business at the University of Cape Town in
Cape Town, South Africa. Magda Marquet, Ph.D. Co-President and
Co-Chief Executive Officer Althea Technologies Dr. Magda Marquet, a
founder of Althea Technologies, has had over twenty years of
experience in the biotechnology industry in the United States and
Europe. She was formerly executive director of pharmaceutical
development at Vical Incorporated. Prior to joining Vical, Dr.
Marquet held process development positions at Amylin
Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation
and Transgene. Dr. Marquet holds a Ph.D in Biochemical Engineering
from the University of Toulouse/INSA. Scott Salka Chief Executive
Officer Ambit Biosciences M. Scott Salka has served at the helm of
several genomics companies. Prior to joining Ambit in 2001, he
served as the president and chief executive officer of two
privately-held genomics companies, Arcaris, Inc. and 454
Corporation. He also previously co-founded one of the first
commercial genomics companies, Sequana Therapeutics, Inc., a
pioneer in the effort to commercialize the international Human
Genome Project. Salka received his M.B.A. from Carnegie Mellon
University and his B.S. in finance from San Diego State University.
James Schaeffer, Ph.D. Executive Director, Worldwide Licensing and
External Research - West Coast Merck Research Laboratories Dr. Jim
Schaeffer joined Merck Research Laboratories in 1986. During his
first 16 years at MRL, he directed research groups focusing
primarily on neuroendocrine-related projects. Schaeffer joined the
Department of External Scientific Affairs in 2003 with primary
responsibility for all neuroscience licensing. Schaeffer moved to
San Diego in 2004 to assume the role of Merck's "Science Scout" on
the West Coast with the responsibility to identify new
opportunities across all therapeutic areas at all stages of
development including enabling technologies. Academic Directors:
Bob Sullivan, Ph.D. Dean UCSD Rady School of Management Robert S.
Sullivan, founding dean of UCSD's Rady School of Management, is an
expert on entrepreneurship, knowledge management, operations and
venture financing. Prior to his arrival at UCSD, Dr. Sullivan
served as dean of UNC's Kenan-Flagler Business School. From 1995 to
1997, Dr. Sullivan served as director of the University of Texas at
Austin's IC2 Institute. Sullivan holds a doctorate in operations
management from Pennsylvania State University, a master's degree in
production management and quantitative methods from Cornell
University and a bachelor's degree in mathematics from Boston
College. Service Provider Directors: David Marino Principal and
Executive Vice President Irving Hughes David Marino specializes in
complex transactions for technology, life science and business
services companies. Marino is a licensed California Real Estate
Broker who has been exclusively representing tenants since 1991,
completing over 10 million square feet of real estate, comprised of
over 600 transactions. Marino has been an early stage angel
investor in over twenty of his clients and related companies and
venture capital funds. Prior to 1991, Marino was employed by
Trammell Crow Company. DATASOURCE: BIOCOM CONTACT: Tim Ingersoll of
BIOCOM, +1-858-455-0300
Copyright
DJ Orthopedics (NYSE:DJO)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
DJ Orthopedics (NYSE:DJO)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024